<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048397</url>
  </required_header>
  <id_info>
    <org_study_id>FIM-BRO-2013-01</org_study_id>
    <nct_id>NCT02048397</nct_id>
  </id_info>
  <brief_title>Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis</brief_title>
  <acronym>FIM-BRO-2013</acronym>
  <official_title>A Pilot Study of Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of Pulmonary Rehabilitation in patients with bronchiectasis (BC) is not
      sufficiently studied. The aim of this study is to assess the clinical and biological response
      of a Pulmonary Rehabilitation Program (PRP) for 12 weeks in BC vs PRP plus hyperproteic oral
      nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB).

      Methods: single center randomized controlled trial, parallel treatment design: Participants
      will be randomized assigned either will receive (n=14) PRP for 60 minutes, two supervised
      sessions per week in the hospital and one unsupervised session at home vs PRP (n=14) plus ONS
      (one can per day).

      Outcome assessments will be performed at baseline, 12 weeks and 24 weeks:

      1.- effort capacity &amp;#8211;cardiopulmonary exercise test-, 2.- body composition
      (anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance, phase
      angle), 3.- peripheral muscle strength (dynamometry and respiratory -PEM (maximum expiratory
      pressure)and PIM (minimum expiratory pressure)-), 4.- spirometry, 5.- respiratory symptoms
      (bronchorrhea, dyspnoea, exacerbations),6.- level of physical activity (IPAQ questionnaire
      plus objective physical activity (WGT3X)), 7.- quality of life (QOL-B-Spain) ,
      8.-psychological symptoms (HASD) and 9.- biological markers of inflammation (leptin,
      adiponectin, interleukin-6, tumor necrosis factor-alpha, ultrasensitive C-reactive protein,
      GPR55 (G protein-coupled receptor 55) RNAm (messenger ribonucleic acid) expression in white
      blood cells) and oxidation (total antioxidant capacity, superoxide dismutase activity,
      8-iso-prostaglandin F2a, Thiobarbituric acid reactive substances).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in oxygen uptake at peak exercise (VO2max) in cardiopulmonary exercise test (Before and after Rehabilitation-at 3 and 6 months)</measure>
    <time_frame>3rd and 6th month visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>Anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peripheral muscle strength</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>Dynamometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in respiratory symptoms (bronchorrhea, dyspnea, exacerbations) at 6 months.</measure>
    <time_frame>3rd and 6th month visits</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Level of physical activity</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>IPAQ questionnaire plus objective physical activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>QOL-B-Spain</description>
  </other_outcome>
  <other_outcome>
    <measure>biological markers of Biological markers of inflammation and oxidation</measure>
    <time_frame>3rd and 6th month visits</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Pulmonary Rehabilitation (PRP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pulmonary Rehabilitation (PRP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Rehabilitation plus oral nutritional supplement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary Rehabilitation</intervention_name>
    <arm_group_label>Pulmonary Rehabilitation (PRP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate</intervention_name>
    <arm_group_label>Pulmonary Rehabilitation plus oral nutritional supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages from 18-80 (both included)

          -  Patients with bronchiectasis, not cystic fibrosis bronchiectasis.

          -  Bronchiectasis diagnosed by high resolution computed tomography (HRCT). of the chest

          -  Patients followed in Bronchiectasis and Cystic Fibrosis Units in the Hospital.

          -  BMI &gt; 18.5 in patients under 65 years old, and &gt; 20kg/m2 in patients over this age.

          -  Ambulatory patients.

        Exclusion Criteria:

          -  Use of oral corticoids.

          -  Respiratory exacerbation. If a patient had a respiratory exacerbation or a recent
             hospital admission, their participation will be postponed for at least 60 days til any
             acute disease is resolved.

          -  Prior oral or parenteral supplements intake.

          -  Traumatological, neurological or cardiovascular diseases that prevent patients from
             performing the training.

          -  Life threatening hemoptysis in the past year.

          -  Patients with cancer, major surgery in the previous three months, participating in
             another study, patients who are pregnant or may become pregnant, patients with acute
             intestinal disease, acute heart failure, severe hepatic failure or dialysis.

          -  Gastrectomy, gastroparesis or other alterations of gastric emptying.

          -  Enteral tube feeding, galactosemia, Fructosemia.

          -  Allergy or known sensitivity to any ingredient of the enteral formula.

          -  Cystic fibrosis.

          -  Included in active list for transplantation.

          -  Drug or alcohol abuse.

          -  No informed consent signed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GABRIEL OLVEIRA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andaluz Health Service</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gabriel Olveira</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Clin Nutr. 2015 Oct 19. pii: S0261-5614(15)00255-1. doi: 10.1016/j.clnu.2015.10.001. [Epub ahead of print]</citation>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchiectasis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

